Olive Leaf Extract Preserved Elastin in Postmenopausal Women Over 12 Weeks

Elastin is the protein that makes skin bounce back. Not the firmness from collagen, but the resilience: the way skin springs back after a facial expression, the way it returns after pressure. In postmenopausal skin, this protein degrades quietly and irreversibly. A November 2025 clinical trial published in Frontiers in Nutrition tested whether olive leaf extract could interrupt that process.

The study

This was a randomized, double-blind, placebo-controlled trial. Sixty-five healthy postmenopausal women between the ages of 45 and 70 were enrolled. One group took 250mg daily of Bonolive, an olive leaf extract standardized to 40% oleuropein, developed by Solabia Nutrition. The other group received a placebo. The trial ran for 12 weeks.

Oleuropein is a polyphenol unique to the olive tree. In the body, it metabolizes into hydroxytyrosol, which contributes additional antioxidant activity. What distinguishes oleuropein from generic antioxidants is its dual action: it suppresses inflammatory signaling through the NF-kB pathway and inhibits advanced glycation end-product (AGE) formation, two of the key mechanisms driving skin aging after menopause.

Elastin levels held

The primary finding was a difference in elastin levels between groups. In the olive leaf extract group, elastin was preserved across 12 weeks. In the placebo group, elastin continued to degrade over the same period.

“Preserved” may sound modest. In this context, it is not. Adult skin does not regenerate elastin in any meaningful quantity. Once elastin is lost, it is not replaced. Preventing further degradation is the only option available, which makes slowing the rate of breakdown clinically significant.

Pentosidine dropped

Blood levels of pentosidine, a type of advanced glycation end-product, also decreased in the olive leaf extract group. Pentosidine forms when proteins and sugars bind non-enzymatically, and in skin it cross-links both collagen and elastin fibers, causing them to stiffen and lose flexibility. The result is skin that is less resilient, less expressive, and visibly older.

Circulating pentosidine is used as a biomarker for tissue-level aging burden. A reduction in this marker suggests that the glycation load on connective tissue was meaningfully reduced over the trial period.

Pore reduction confirmed by dermoscopy

A dermoscopy subgroup analysis captured an additional change. Participants taking olive leaf extract showed a significant reduction in pore size between weeks 6 and 12. At the 12-week mark, they had fewer visible pores compared to the placebo group.

Pore size is directly connected to skin elasticity. When the tissue surrounding pores loses elasticity, it sags and the pores appear enlarged. The simultaneous preservation of elastin and reduction in pore appearance follows that logic directly.

Dosage and label reading

The trial used 250mg daily, standardized to 40% oleuropein. That standardization detail matters. Many olive leaf extract products on the market carry oleuropein concentrations of 6% to 20%. A product label that says “olive leaf extract” without specifying oleuropein content cannot be compared to this study’s conditions. Look for the phrase “standardized to 40% oleuropein” on the label.

Anyone taking anticoagulants such as warfarin or aspirin should confirm with a healthcare provider before adding olive leaf extract, as oleuropein has mild effects on platelet function.

The postmenopause context

Estrogen decline after menopause reduces the rate of collagen and elastin synthesis while accelerating degradation. Collagen loss of approximately 30% has been documented in the five years following menopause. Glycation rates increase over the same period. The combination creates a compounding skin aging burden that acts faster than chronological age alone would predict.

Olive leaf extract has been studied within the Mediterranean diet context for decades. What this trial adds is a specific, measurable application to postmenopausal skin aging, with a randomized controlled design, validated biomarkers, and a commercially available branded ingredient. For the Bonolive formulation specifically, this represents a meaningful addition to the clinical evidence base.